

## **Running Title:** Atrial Fibrillation Expenditures in the US

Healthcare Expenditure on Atrial Fibrillation in the United States:

The Medical Expenditure Panel Survey 2016-2021

Claudia See MD MBA<sup>1</sup>, Scott Grubman MD MHS<sup>2</sup>, Nisarg Shah BS<sup>3</sup>, Jiun-Ruey Hu<sup>4</sup>, Michael Nanna, MD, MHS<sup>5</sup>, James V. Freeman MD, MPH, MS<sup>5,6</sup>, Karthik Murugiah MBBS<sup>5,6</sup>

<sup>1</sup>Division of General Internal Medicine, University of California, San Francisco, CA

<sup>2</sup>Division of General Internal Medicine, The Mount Sinai Hospital, New York, NY

<sup>3</sup>Yale School of Medicine, New Haven, CT

<sup>4</sup>Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>5</sup>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

<sup>6</sup>Center for Outcomes Research and Evaluation, Yale New Haven Health Services Corporation, New Haven, Connecticut, USA

**Word Count:** 3,333

**Financial Support:** Dr. See received support from the Yale School of Medicine 2023

Fellowship for Medical Student Research. Dr. Murugiah received support from the National

Heart, Lung, and Blood Institute of the National Institutes of Health (under award

K08HL157727). Dr. Nanna reports research support from the American College of Cardiology

(George F and Ann Harris Bellows Foundation), the Patient-Centered Outcomes Research

Institute, the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342),

and the National Institute on Aging/National Institutes of Health (GEMSSTAR award: R03AG074067).

**Relationship with Industry:** Dr. Freeman reports research support from the NIH/NHLBI and the American College of Cardiology National Cardiovascular Data Registry and advisory board/consulting with Boston Scientific, Medtronic, Abbott, Biosense Webster, and PaceMate.

Dr. Nanna reports consulting from HeartFlow, Inc., Novo Nordisk, and Merck.

**Address for Correspondence:**

Claudia See, MD MBA

1239 4th Ave, San Francisco, CA 94122

Tel: 858 472 7605. [claudia.see@ucsf.edu](mailto:claudia.see@ucsf.edu).

## **ABSTRACT:**

**Objectives:** To provide a contemporary nationally representative assessment of atrial fibrillation (AF) and atrial flutter (AFL) expenditures in the United States.

**Background:** AF prevalence is rising over time and management is evolving. However, there has been no contemporary national assessment of expenditures of AF.

**Methods:** Using Medical Expenditure Panel Survey (MEPS) 2016-2021 data, we identified individuals with AF or AFL using International Classification of Disease (ICD)-10 codes and reported total and categorized expenditures. Using two-part and gamma regression models, respectively, we estimated the incremental expenditures with AF for the entire population and for individuals with common coexisting comorbidities. Among individuals with AF, we identified characteristics associated with higher expenditures.

**Results:** Of a weighted surveyed population of 248,067,064 adults, 3,564,763 (1.4%) had AF. Mean age was  $71.9 \pm 10.6$  years and 45.7% were female. Mean unadjusted annual total healthcare expenditure for individuals with AF was  $\$25,451 \pm \$1,100$  compared with  $\$9,254 \pm \$82$  for individuals without AF. The highest spending categories were inpatient visits ( $\$7,975 \pm \$733$ ) and prescriptions ( $\$6,505 \pm \$372$ ). AF expenditures increased over the study period by 11.1%. After adjustment, the incremental annual expenditure attributable to AF was  $\$6,188$  per person. Incremental expenditures with AF were highest for those with cancer ( $\$11,967$ , 95% CI  $\$4,410 - \$19,525$ ), while AF did not significantly increase expenditures in HF ( $-\$2,756$ , 95% CI  $-\$10,048 - \$4,535$ ). Modified Charlson Comorbidity Index of 1 or  $\geq 2$ , uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditures.

**Conclusion:** AF is associated with substantial healthcare expenditures which are increasing over time. With changes in screening and management, expenditures need periodic reassessments.

**Word Count:** 272

## **CONDENSED ABSTRACT:**

**Introduction:** AF prevalence is rising, but contemporary national expenditure assessments are lacking.

**Methods:** Two-part and gamma regression models of MEPS 2016-2021 data (all-payer cross-sectional US survey) estimated AF effect on healthcare expenditures.

**Results:** Of 248,067,064 adults, 1.4% had AF, with mean age 72.1 years and 45.7% female.

Mean unadjusted annual expenditure was \$25,451 ± \$1,100 (\$9,254 ± \$82 without AF).

Incremental adjusted annual expenditure attributable to AF was \$6,188. Modified CCI of 1 or ≥2, uninsured status, cancer, poor income level, ASCVD, COPD, and later survey year were associated with higher expenditure.

**Discussion:** AF expenditures are substantial and increasing.

**Word Count:** 99

### **Condensed Abstract Abbreviations:**

AF = Atrial Fibrillation

CCI = Charlson Comorbidity Index

MEPS = Medical Expenditure Panel Survey

NHEA = National Health Expenditure Accounts

US = United States

### **Manuscript Abbreviations:**

AAD = Antiarrhythmic Drug

AF = Atrial Fibrillation

AHRQ = Agency of Healthcare Research and Quality

ASCVD = Atherosclerotic Cardiovascular Disease

CABANA = Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation

CCI = Charlson Comorbidity Index

COPD = Chronic Obstructive Pulmonary Disease

CPI = Consumer Price Index

DOAC = Direct-Acting Oral Anticoagulants

ED = Emergency Department

FPL = Federal Poverty Line

GED = General Educational Development

HF = Heart Failure

HS = High School

MEPS = Medical Expenditure Panel Survey

NCHS = National Center for Health Statistics

NHEA = National Health Expenditure Accounts

NHIS = National Health Interview Survey

OR = Odds Ratio

SD = Standard Deviation

US = United States

IQR = Interquartile Range

## 1 INTRODUCTION

2 Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 to 6.1  
3 million people in the United States (US) (1). Over time, with an aging population and potentially  
4 increased detection due to improved and more widespread monitoring devices, the prevalence of  
5 AF has been rising and the prevalence is estimated to be 12.1 million by 2030 (2).

6  
7 AF is associated with significant morbidity, including hospitalizations and risk for cardiovascular  
8 and cerebrovascular events (3,4). Given these characteristics, AF is associated with high  
9 healthcare expenditures (5,6). The management of AF has been evolving, with increased use of  
10 antiarrhythmics and procedures to maintain sinus rhythm as well as increased use of direct-acting  
11 oral anticoagulants (DOACs) and left atrial appendage occlusion for stroke prevention, which  
12 can also affect expenditures. However, contemporary studies of US national healthcare  
13 expenditures for AF care have been lacking. Further, AF frequently co-exists with other  
14 important cardiac and non-cardiac comorbidities such as heart failure (HF), atherosclerotic  
15 cardiovascular disease (ASCVD), chronic obstructive pulmonary disease (COPD), and cancer,  
16 all of which may complicate their management (7-9). How contemporary expenditures of these  
17 conditions are influenced by co-existent AF has not been well evaluated.

18  
19 Accordingly, the aim of this study was to report current annual healthcare expenditures and  
20 recent trends for individuals with AF (categorizing expenditures across medical service  
21 categories such as hospitalizations and prescriptions), estimate the incremental expenditures  
22 nationally attributable to AF, and identify the characteristics of individuals with AF who  
23 experience higher expenditures.



## 24 **METHODS**

### 25 **Data Sources**

26 The Medical Expenditure Panel Survey (MEPS) is an annual cross-sectional survey of US  
27 families and individuals by the Agency of Healthcare Research and Quality (AHRQ). It is the  
28 largest all-payer nationally representative annual cross-sectional survey of medical expenditures  
29 of the US civilian, noninstitutionalized population (10). MEPS collects data on demographic  
30 characteristics, health conditions, health status, use of medical services, charges and source of  
31 payments, access to care, satisfaction with care, health insurance coverage, income, and  
32 employment. Overall response rates in the years 2016 to 2021 were approximately 22-46% (11).

33  
34 The panel design of the survey includes 5 rounds of interviews covering 2 full calendar years.  
35 Every year, a new panel of about 15,000 sample households is selected. The set of households  
36 selected for each panel is a subsample of households participating in the previous year's National  
37 Health Interview Survey (NHIS) conducted by the National Center for Health Statistics (NCHS).

38  
39 Data from the MEPS Household Component Full-Year Consolidated Data Files and Medical  
40 Conditions Files were pooled across the years 2016 to 2021 and then merged using two  
41 variables—patient identifier variable ‘DUPERSID’ and survey ‘Year.’ The study was limited to  
42 2016 and after because the ICD-9 codes used in MEPS data before 2016 were limited to three-  
43 digits for confidentiality reasons and could not distinguish AF from other cardiac arrhythmias.  
44 For 2016 and 2017, the two-digit panel number from variable ‘PANEL’ was added in front of all  
45 DUPERSIDs per the recommendation of AHRQ (12) to be consistent across all survey years.

46 Families and individuals were assigned weights based on demographic proportions in the overall

47 US population (13). The NHIS sample design underwent several changes between 2016-2021,  
48 such as discontinuation of oversampling of Asian, Black, and Hispanic minority groups (14) in  
49 favor of oversampling of Veterans and middle-sized states (15,16). To compensate for low  
50 response rates during the COVID-19 pandemic, MEPS extended the duration of its survey panels  
51 by one year (11).

52

53 As all data and materials are de-identified and publicly available online  
54 at <https://meps.ahrq.gov/mepsweb/>, this study was exempt from institutional review board  
55 approval by Yale University.

## 56 **Study Population**

57 The study population included all adults aged 18 years old or older. AF and atrial flutter (AFL)  
58 was identified using the International Classification of Disease (ICD)-10 code “I48.” Similarly,  
59 ASCVD, HF, COPD, and cancer were identified using appropriate ICD-10 codes (see  
60 Supplemental Table 1). The weighted population size was estimated as the average annual  
61 population size for the pooled period, based on the recommendation from AHRQ on pooling  
62 (17).

63

## 64 **Variables and Pre-Processing**

65 Age was categorized into 18-44, 45-64, 65-84, and  $\geq 85$  years old, and sex as male or female.  
66 Race/ethnicity was categorized as non-Hispanic White, Hispanic, non-Hispanic Black, and non-  
67 Hispanic Asian and other/mixed race. Marital status was categorized as married, never married,  
68 and divorced/widowed/separated. Insurance status was categorized as private, Medicare, other

69 public, or uninsured. Education was categorized as no degree, general educational development  
70 (GED) or high school (HS) graduate, bachelor's degree, master or doctorate degree, and other  
71 degree. Family income was categorized as poor (families with income less than or equal to the  
72 federal poverty line [FPL]), near-poor (100-125% of the FPL), low income (125-200% of the  
73 FPL), middle income (200-400% of the FPL), and high income (>400% of the FPL) per the  
74 MEPS poverty status variable. In the multivariable models, age and survey year were treated as  
75 continuous variables. The Stata 'charlson' package was used to calculate the Charlson  
76 Comorbidity Index (CCI) score (18). A higher score represents more comorbid conditions.

77  
78 Total medical expenditure was defined as the sum of direct payments for care across 8 medical  
79 service categories: inpatient hospitalization stays, outpatient and office-based visits, prescription  
80 medication, emergency department (ED) visits, dental visits, home healthcare, and others  
81 (including dental and vision expenditures). Payments were combined across 10 payers such as  
82 private insurance, Medicare, Medicaid, Tricare, out-of-pocket, and other. All expenditures and  
83 incomes in our analyses were inflation adjusted to year 2021 using the Consumer Price Index  
84 (CPI). Home health expenditures were derived by summed home health agency and home health  
85 non-agency expenditure MEPS variables. Other expenditures were derived by summed dental,  
86 vision, and 'other' expenditure MEPS variables.

## 87 **Statistical Methods**

88 Continuous variables were presented as mean  $\pm$  standard deviation (SD) and categorical  
89 variables as proportions. Continuous and categorical variables were compared using the  
90 Wilcoxon rank-sum test and chi-squared tests, respectively. A two-sided p-value of <0.05 was  
91 used for statistical significance. MEPS survey weights were applied using the 'svy' function in

92 Stata. Statistical analysis was conducted using Stata Statistical Software: Release 18 (College  
93 Station, TX).

94

## 95 **Modeling Healthcare Expenditure**

96 For expenditure data which are typically right-skewed (19), a two-part model is commonly  
97 used—the first model is a logistic or probabilistic (probit) regression model which estimates the  
98 probability of zero versus positive expenditures, and the second model, conditional on having a  
99 positive annual healthcare expenditure, such as a generalized linear model with gamma  
100 distribution and a logarithmic-link function that estimates the average expenditure per capita  
101 (20,21).

102

103 Accordingly, to estimate incremental total healthcare expenditure attributable to AF, a two-part  
104 regression model was created using the entire pooled population with and without AF.

105 Covariates included in multivariable adjustment were AF, age, sex, race/ethnicity, survey year,  
106 CCI, poverty level, education status, marital status, and insurance status. National estimates of  
107 AF expenditure were extrapolated by multiplying the incremental expenditure per person by the  
108 survey weighted number of individuals with AF in the US in our study.

109

110 Second, incremental expenditures attributable to AF within subpopulations of individuals with 4  
111 other common chronic comorbidities of cancer, ASCVD, COPD, and HF were estimated by  
112 creating a gamma regression model for each subpopulation and calculating average marginal  
113 effect with 95% confidence intervals (CI). Gamma models were used instead of two-part models  
114 because of the low prevalence of individuals with no expenditures within the comorbidity

115 subpopulations. For these gamma regression models, a ‘modified’ CCI was used by excluding  
116 the 4 comorbidities of ASCVD, cancer, HF, and COPD (22), resulting in 3 final score categories  
117 of 0, 1, and  $\geq 2$ . This was done to enable inputting these comorbidities as separate covariates into  
118 the model to study their individual effects.

119  
120 Third, individual characteristics associated with increased total healthcare expenditures were  
121 determined by creating a gamma regression model only for individuals with AF and calculating  
122 odds ratios (OR) with 95% CI. For this gamma regression model, the ‘modified’ CCI covariate  
123 was also used.

124

## 125 **RESULTS**

### 126 **Study Population Characteristics**

127 The average annual surveyed population was 22,911 US adults aged  $\geq 18$  years. Of these, 98.6%  
128 had complete data (n=22,583), equivalent to a survey weighted population of 248,067,064 adults.  
129 Within this population with complete data, 1,902 survey respondents had AF, equivalent to a  
130 survey weighted population of 3,564,763 adults and an overall AF prevalence of 1.4%.

131

132 Table 1 shows demographics and comorbidities of the overall population, with and without AF.

133 Among individuals with AF, the mean age was  $71.9 \pm 10.6$  years, 45.7% were female, and

134 89.0% were non-Hispanic white. The median CCI was 1 (Interquartile Range [IQR] 0-1).

135 Among individuals without AF, the mean age was  $47.5 \pm 18.2$  years, 51.8% were female, and

136 62.3% were non-Hispanic white. The median CCI was 0 [0-0] for individuals without AF. The

137 prevalence of ASCVD between individuals with and without AF was 34.7% vs. 5.2%, cancer

138 12.6% vs. 3.4%, COPD 9.5% vs. 2.2%, and HF 7.0% vs. 0.6% respectively (all  $p < 0.001$ ).

139

#### 140 **Healthcare Expenditures with AF**

141 For individuals with AF, the mean unadjusted annual total healthcare expenditure in terms of  
142 2021 inflation-adjusted dollars was  $\$25,451 \pm \$1,100$  (Table 1) compared with  $\$9,254 \pm \$82$  for  
143 individuals without AF ( $p < 0.001$ ). The highest expenditures among service categories in AF  
144 were inpatient visits ( $\$7,975 \pm \$733$ ), followed by prescriptions ( $\$6,505 \pm \$372$ ) and office-  
145 based visits ( $\$4,716 \pm \$247$ ). Annual expenditures for individuals with AF were higher than  
146 those without AF across all service categories.

147

148 In comparison, mean unadjusted annual total healthcare expenditure among individuals with  
149 other chronic diseases - HF, cancer, ASCVD, and COPD - were  $\$33,753 \pm \$2,026$ ,  $\$25,212 \pm$   
150  $\$998$ ,  $\$23,096 \pm \$530$ , and  $\$21,725 \pm \$675$  respectively.

151

152 Trends in mean unadjusted annual expenditure among individuals with AF over 2016-2021 are  
153 shown in Figure 1. Over the study period, there was a 11.1% ( $\$2,635$ ) increase in annual total  
154 expenditures, 63.8% ( $\$1,667$ ) increase in outpatient expenditures, 31.6% ( $\$1,193$ ) increase in  
155 office-based visits, 97.8% ( $\$493$ ) increase in emergency department expenditures, 9.0% ( $\$133$ )  
156 increase in home health expenditures, and 49.0% ( $\$485$ ) increase in other expenditures. There  
157 was a decrease of 14.6% ( $\$1,129$ ) in inpatient expenditures and 3.1% ( $\$208$ ) in medication  
158 expenditures. In comparison, among individuals without AF, there was a 23.1% ( $\$1,464$ )  
159 increase in annual total expenditures, driven by a 41.9% ( $\$672$ ) increase in office-based  
160 expenditures, 87.0% ( $\$490$ ) increase in outpatient expenditures, 21.1% ( $\$335$ ) increase in

161 medication expenditures, and 48.0% (\$228) increase in other expenditures. There was a 13.9%  
162 (\$214) decrease in inpatient expenditures, 4.9% (\$16) decrease in home health, and a 12.4%  
163 (\$30) decrease in ED expenditures.

164  
165 After adjusting for demographics, comorbidities, and survey year, the incremental mean annual  
166 healthcare expenditure attributable to AF estimated from the two-part regression model was  
167 \$6,188 per person (95% CI \$5,075-\$7,301). With a survey weighted AF population of 3,564,763  
168 as shown in Table 1, this translates to an overall national healthcare expenditure of \$22.1 billion  
169 per year.

170  
171 Incremental expenditures attributable to AF within subpopulations of individuals with the 4 other  
172 common chronic comorbidities of cancer, ASCVD, COPD, and HF were estimated using a  
173 gamma regression model for each subpopulation (Table 2). From largest to smallest, the average  
174 marginal effects (95% CI) of having AF in addition to cancer, COPD, or ASCVD were \$11,967  
175 (\$4,410-\$19,525), \$8,104 (\$2,594 - \$13,613), and \$6,721 (\$3,684 - \$9,758) respectively. HF did  
176 not significantly impact AF expenditures with an average marginal effect of -\$2,756 (-\$10,048 -  
177 \$4,535) (Central Illustration).

178  
179 After adjustment for demographics, comorbidities, and survey year in a gamma regression model  
180 (Table 3), the variables associated with increased total healthcare expenditure among individuals  
181 with AF were modified CCI of  $\geq 2$  [OR 1.95 (95% CI 1.53-2.50),  $p < 0.001$ ] and 1 [OR 1.28 (95%  
182 CI 1.07-1.54),  $p = 0.009$ ], uninsured status [OR 1.83 (95% 1.13-2.96),  $p = 0.014$ ], cancer [OR 1.76  
183 (95% CI 1.35-2.29),  $p < 0.001$ ], poor income level [OR 1.39 (95% CI 1.02-1.88),  $p = 0.037$ ],

184 ASCVD [OR 1.37 (95% CI 1.17-1.60),  $p < 0.001$ ], COPD [OR 1.31 (95% CI 1.01-1.69),  
185  $p = 0.039$ ], and later survey year [OR 1.07 (95% CI 1.03-1.12),  $p = 0.002$ ].

186

## 187 **DISCUSSION**

188 Individuals with AF had mean unadjusted annual total healthcare expenditures nearly 3 times  
189 that of individuals without AF and total expenditures increased by 11% from 2016 to 2021. After  
190 adjustment for demographics, comorbidities, and survey year, the incremental annual  
191 expenditure was ~\$6,000 per person with AF, translating to over \$22 billion in healthcare  
192 expenditures annually from AF. Among individuals with AF, a higher comorbidity burden,  
193 presence of cancer, uninsured status, and a more recent survey year were associated with higher  
194 expenditures.

195

196 Our findings build on prior studies focusing on healthcare expenditures in AF. In a systematic  
197 review of studies from 1990-2009, Wolowacz et al. found the direct expenditures of AF across  
198 the 5 studies from the US to vary from as low as \$2,000 per patient-year to as high as \$14,200  
199 (23). In another study, using a database of commercially insured patients from 2017-2020,  
200 Deshmukh et al. found mean total annual healthcare expenditure for patients with AF to be much  
201 higher at \$63,031 (\$27,896 more than those without AF) (24). Additionally, in a 1999-2002  
202 privately insured database for 2 million enrollees, Wu et al. reported that the excess annual direct  
203 expenditure of AF was \$12,349 ( $p < 0.001$ ), with individuals with AF having expenditures  
204 approximately 5 times higher than individuals without AF (\$15,553 versus \$3,204, respectively)  
205 (25).

206



207 In our study, we found mean unadjusted annual healthcare expenditures for individuals with AF  
208 to be \$25,241 per person per year, and after adjustment for demographics and comorbidities, the  
209 presence of AF was associated with an additional \$6,188 incremental healthcare expenditure.  
210 Additionally, although AF is often considered to be a condition associated with other chronic  
211 conditions, AF is also, in itself, a significant driver of expenditures. Healthcare expenditures for  
212 individuals with AF were noted to be in a similar range to the total expenditures for individuals  
213 with other common comorbidities such as ASCVD, cancer, and COPD. With increasing  
214 prevalence of AF and healthcare expenditures comparable to other major chronic conditions,  
215 healthcare expenditures for AF deserve greater public attention and policy focus.

216

217 Compared to the wide range of expenditures reported by prior studies, our estimates are likely  
218 more accurate and representative of current expenditures among individuals with AF in the US  
219 as the MEPS is considered a national standard in assessing expenditures of medical conditions in  
220 the population, measuring both direct payments for healthcare services and out-of-pocket  
221 payments, and includes participants across all insurance statuses.

222

223 Inpatient (hospitalization) expenditures were the largest contributor to expenditures among  
224 individuals with AF—consistent with prior studies (5,23)—and accounted for nearly a third of  
225 the total expenditure. Hospitalizations among individuals with AF are often related to the  
226 presence of multiple comorbidities or complications related to AF such as stroke,  
227 thromboembolism, and anticoagulant-related issues (24,26). However, use of ablation procedures  
228 and cardioversions to maintain sinus rhythm and left atrial appendage for stroke prevention may  
229 also be an increasing contributor to hospitalizations. One reason for the increase in total

230 healthcare expenditures from 2016-2021 could be increasing use of catheter ablation strategies  
231 for AF patients, which have grown by 10% per year (27). However, studies have suggested that  
232 ablation may reduce downstream costs compared to medical therapy. In the Catheter Ablation vs  
233 Antiarrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA) trial, catheter ablation of  
234 AF was economically attractive compared to drug therapy based on the incremental cost-  
235 effectiveness ratio of \$57,893 per quality-adjusted life year gained (28). It is possible that over  
236 time the increased use of ablations may translate to decreased hospitalization costs. The strength  
237 of the ongoing survey design of MEPS can allow periodic reassessment of hospitalization costs.  
238 Future studies distinguishing expenditures due to elective vs. emergent hospitalizations can  
239 improve our understanding of expenditures related to AF. Ultimately, as hospitalizations  
240 contribute significant burden in expenditures with AF (29), they should also be afforded  
241 significant policy focus to improve patient care.

242  
243 Prescription expenditures were the second largest contributor to AF expenditures. A recent  
244 innovation in AF management has been the emergence of DOACs and their use has been  
245 increasing use of over the past decade (30). Besides DOACs, increasing antiarrhythmic drug  
246 usage may also contribute to increasing prescription expenditures (31). Despite high prescription  
247 expenditures, our study showed a small decrease in prescription expenditures of 3.1% (\$208)  
248 from 2016-2021. This may be because most DOACs were already approved prior to our study's  
249 start year of 2016 (32). With some DOACs potentially becoming available in generic form in the  
250 future, prescription expenditures may decrease substantially over the next decade. Furthermore,  
251 medications such as DOACs reduce severe bleeding events including intracranial bleeding and  
252 left atrial appendage occlusion.

253

254 Among individuals with AF, the mean unadjusted annual total expenditure increased over time  
255 by \$2,636, or 11.1%. Over the 2016-2021 study period, there were increases across all medical  
256 service categories except for inpatient expenditures (the category with the largest contribution to  
257 expenditures), which decreased by 14.6%, and medication expenditures, which decreased by  
258 3.1%. A closer look at the trend in inpatient expenditures shows that there was an increasing  
259 trend of hospitalization expenditures prior to the COVID-19 pandemic (22.0% from 2016-2019).  
260 However, since then, the inpatient expenditures were observed to decrease by 29.9% from 2019-  
261 2021, which match reported declines in AF admission rates and new diagnoses during COVID-  
262 19 (33-35). The drivers of this recent decrease are unclear. This may be related to the competing  
263 risk of mortality, which was high among the elderly population with COVID-19—especially  
264 among those with multiple comorbidities. Alternatively, there may have been systemic declines  
265 in hospitalizations or average hospitalization expenditures among individuals with AF. Studies  
266 are needed to compare the causes, frequency, and expenditures of hospitalizations among  
267 individuals with AF before and after the pandemic.

268

269 A novel aspect of our study is the evaluation of the incremental expenditures attributable to AF  
270 among individuals with other commonly coexisting chronic diseases. Incremental expenditures  
271 attributable to AF were greatest in cancer (\$11,967), suggesting that coexistence or development  
272 of AF is a significant cost driver among individuals with cancer. This may be related to increased  
273 hospitalizations or length of stay and increased prescription expenditures. On the other hand, AF  
274 did not change expenditures for individuals with HF, which is surprising given that AF is  
275 associated with worse prognosis in HF (36) and can be expected to increase costs. However, a

276 lack of effect on expenditures when these conditions co-exist may potentially be due to an  
277 overlap in shared medications, treatments for these two chronic cardiac conditions, or  
278 unidentified confounders in baseline characteristics.

279  
280 In the coming years, the total expenditures for individuals with AF may continue to increase.  
281 Newer classes of AF medications and the increasing use of procedural and device therapies may  
282 be drivers of expenditures. On the other hand, with more efficacious treatments and monitoring,  
283 there may be reductions in other expenditures, such as decreased hospitalizations. The ongoing  
284 survey and consistent methodology are strengths of using the MEPS database, and allow for  
285 close monitoring of patterns of change in expenditures over time.

286  
287 Our study has several limitations. First, due to high rates of comorbidities among individuals  
288 with AF, there may be residual confounding after multivariable adjustment making it harder to  
289 assess independent effects of AF on expenditure. Second, our study overlapped with the COVID-  
290 19 pandemic from 2019-2021. Thus, there may be short-term changes in expenditure patterns  
291 that warrant reassessment in coming years. Third, because the MEPS database lacks information  
292 on procedures, we are unable to report expenditures of AF-associated procedures such as  
293 ablation and left atrial appendage closure and how they relate to expenditures as they are likely  
294 captured as part of inpatient expenditures. MEPS also lacks participant representation from  
295 institutionalized individuals including nursing home residents (37). Also, our study does not  
296 account for indirect expenditures incurred by individuals, such as income lost due to reduced  
297 productivity and caregiver expenses. Thus, actual expenditures incurred by individuals with AF  
298 may be higher than the direct expenditures reported in the study.

299

300 An additional limitation is that the self-reported nature of MEPS data can lead to underreporting  
301 of expenditures. For personal healthcare spending estimates, MEPS data have been reported to  
302 be consistently lower than National Health Expenditure Accounts (NHEA) data from the Centers  
303 for Medicare and Medicaid Services, which are known as the official estimates of total  
304 healthcare spending in the US. Specifically, MEPS reports \$240.3 billion or 17.6% less  
305 expenditures than the adjusted NHEA total expenditures (38). These different may be caused by  
306 different factors including sampling bias, non-response bias, attrition, and other measurement  
307 errors (39).

## 308 **CONCLUSION**

309 Individuals with AF have high and increasing healthcare expenditures that amount to over \$22  
310 billion in US spending every year. Further, the co-existence of AF among individuals with  
311 comorbidities of ASCVD, cancer, and COPD significantly increased expenditures. Given these  
312 high expenditures and increasing prevalence, AF warrants increased focus from healthcare policy  
313 makers to alleviate financial burden and improve patient outcomes. In parallel, there are  
314 continued advancements in AF management, and the resulting improvements in cardiovascular  
315 health can lead to reductions in long-term healthcare expenditures. Thus, there is a need to  
316 periodically reassess expenditures.

317

318

319 **PERSPECTIVES**

320 **Competency in Systems-Based Practice 1:**

321 Individuals with AF incur \$25,451 of healthcare expenditures per year and expenditures are  
322 increasing over time. The incremental expenditure per year attributable to AF is \$6,188 after  
323 multivariable adjustment. This translates to an overall national healthcare expenditure of \$22.1  
324 billion per year. AF increases expenditures further among individuals with other chronic  
325 diseases.

326 **Competency in Systems-Based Practice 2:**

327 Individuals with AF who were surveyed in more recent years, had more comorbidities including  
328 cancer, ASCVD, and COPD, and were poor and uninsured had higher annual healthcare  
329 expenditures after multivariable adjustment.

330 **Competency in Patient Care and Procedural Skills:**

331 Given high expenditures, AF needs increased focus of policy makers. With increased detection  
332 and changes in treatment of AF, expenditures need continual assessments.

333 **Translational Outlook:**

334 This study, which uses an all-payer nationally representative annual cross-sectional survey of  
335 medical expenditures of the United States civilian noninstitutionalized population, found that 1)  
336 individuals with AF had mean unadjusted annual total healthcare expenditures nearly 3 times  
337 that of individuals without AF, with total expenditures increasing by 11.1% from 2016 to 2021;  
338 2) after multivariable adjustment, the incremental annual expenditure was approximately \$6,000  
339 per person with AF, translating to over \$22 billion in healthcare expenditures annually; and 3)  
340 among individuals with AF, a higher comorbidity burden, presence of cancer, ASCVD, or  
341 COPD, uninsured status, poor income level, and later survey year were associated with higher

342 expenditures. With an aging US population and new screening and management methods, further

343 studies are needed to reassess trends in healthcare expenditures in AF over time.

344

345

346 **ACKNOWLEDGEMENTS**

347 We thank the Yale StatLab student consultant team for their statistical advice.

348



## 349 REFERENCES

350


- 351 1. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the  
352 management of patients with atrial fibrillation: a report of the American College of  
353 Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart  
354 Rhythm Society. *J Am Coll Cardiol* 2014;64:e1-76.
- 355 2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and  
356 future incidence and prevalence of atrial fibrillation in the U.S. adult population. *Am J*  
357 *Cardiol* 2013;112:1142-7.
- 358 3. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in  
359 the 21st Century. *Circulation Research* 2020;127:4-20.
- 360 4. Benjamin EJ, Muntner P, Alonso A et al. Heart Disease and Stroke Statistics-2019  
361 Update: A Report From the American Heart Association. *Circulation* 2019;139:e56-e528.
- 362 5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total  
363 incremental health care costs in patients with atrial fibrillation in the United States. *Circ*  
364 *Cardiovasc Qual Outcomes* 2011;4:313-20.
- 365 6. Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging  
366 epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs.  
367 *Eur Heart J Qual Care Clin Outcomes* 2022;8:187-194.
- 368 7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of  
369 Atrial Fibrillation on the Risk of Death. *Circulation* 1998;98:946-952.
- 370 8. Chamberlain AM, Alonso A, Gersh BJ et al. Multimorbidity and the risk of  
371 hospitalization and death in atrial fibrillation: A population-based study. *American Heart*  
372 *Journal* 2017;185:74-84.
- 373 9. Jani BD, Nicholl BI, McQueenie R et al. Multimorbidity and co-morbidity in atrial  
374 fibrillation and effects on survival: findings from UK Biobank cohort. *EP Europace*  
375 2017;20:f329-f336.
- 376 10. Cohen JW, Cohen SB, Banthin JS. The medical expenditure panel survey: a national  
377 information resource to support healthcare cost research and inform policy and practice.  
378 *Med Care* 2009;47:S44-50.
- 379 11. MEPS-HC Response Rates by Panel Display page in Printer Friendly Format printer-  
380 friendly. Agency for Healthcare Research and Quality: Retrieved from:  
381 [https://meps.ahrq.gov/survey\\_comp/hc\\_response\\_rate.jsp](https://meps.ahrq.gov/survey_comp/hc_response_rate.jsp).
- 382 12. Survey MEP. Question: Does the DUPERSID variable uniquely identify a person in the  
383 MEPS survey? : Agency for Healthcare Research and Quality: Retrieved from  
384 [https://meps.ahrq.gov/about\\_meps/faq\\_answers.jsp?FAQID=127&ChooseCategory=5&k](https://meps.ahrq.gov/about_meps/faq_answers.jsp?FAQID=127&ChooseCategory=5&keyword=)  
385 [eyword=](https://meps.ahrq.gov/about_meps/faq_answers.jsp?FAQID=127&ChooseCategory=5&keyword=).
- 386 13. MEPS HC-231: 2021 Medical Conditions. Agency for Healthcare Research and Quality:  
387 Retrieved from: [https://meps.ahrq.gov/data\\_stats/download\\_data/pufs/h231/h231doc.pdf](https://meps.ahrq.gov/data_stats/download_data/pufs/h231/h231doc.pdf).
- 388 14. MEPS HC-192 2016 Full Year Consolidated Data File. Agency for Healthcare Research  
389 and Quality, August 2018:Retrieved from  
390 [https://meps.ahrq.gov/data\\_stats/download\\_data/pufs/h192/h192doc.pdf](https://meps.ahrq.gov/data_stats/download_data/pufs/h192/h192doc.pdf).
- 391 15. MEPS HC-209 2018 Full Year Consolidated Data File. Agency for Healthcare Research  
392 and Quality, August 2020:Retrieved from:  
393 [https://meps.ahrq.gov/data\\_stats/download\\_data/pufs/h209/h209doc.pdf](https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf).

- 394 16. MEPS HC-231 2021 Medical Conditions. Agency for Healthcare Research and Quality,  
395 August 2023:Retrieved from  
396 [https://meps.ahrq.gov/data\\_stats/download\\_data/pufs/h209/h209doc.pdf](https://meps.ahrq.gov/data_stats/download_data/pufs/h209/h209doc.pdf).
- 397 17. MEPS HC-036: 1996-2015 Pooled Linkage Variance Estimation File - 4.0 Adjustment of  
398 Analytic Weight Variable. Agency for Healthcare Research and Quality (AHRQ),  
399 September 2017: Retrieved from:  
400 [https://meps.ahrq.gov/data\\_stats/download\\_data/pufs/h36/h36u15doc.shtml#40Other](https://meps.ahrq.gov/data_stats/download_data/pufs/h36/h36u15doc.shtml#40Other).
- 401 18. Stagg V. Charlson comorbidity index macro. University of Calgary:Retrieved from  
402 <http://fmwww.bc.edu/RePEc/bocode/c/charlson.html>.
- 403 19. William W. Yu SM. Examination of Skewed Health Expenditure Data from the Medical  
404 Expenditure Panel Survey (MEPS). Agency for Healthcare Research and Quality  
405 Working Paper No. 04002, 2004.
- 406 20. Klein S, Jiang S, Morey JR et al. Estimated Health Care Utilization and Expenditures in  
407 Individuals With Heart Failure From the Medical Expenditure Panel Survey. *Circ Heart*  
408 *Fail* 2021;14:e007763.
- 409 21. Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaecian B. Expenditure on Heart Failure in  
410 the United States: The Medical Expenditure Panel Survey 2009-2018. *JACC Heart Fail*  
411 2022;10:571-580.
- 412 22. TABLE 1. ICD-9-CM and ICD-10 Coding Algorithms for Charlson Comorbidities.  
413 Manitoba Centre for Health Policy: University of Manitoba.
- 414 23. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda J-G, Van Gelder IC. The cost  
415 of illness of atrial fibrillation: a systematic review of the recent literature. *EP Europace*  
416 2011;13:1375-1385.
- 417 24. Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs  
418 associated with a diagnosis of incident atrial fibrillation. *Heart Rhythm O2* 2022;3:577-  
419 586.
- 420 25. Wu EQ, Birnbaum HG, Mareva M et al. Economic burden and co-morbidities of atrial  
421 fibrillation in a privately insured population. *Curr Med Res Opin* 2005;21:1693-9.
- 422 26. Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. StatPearls. Treasure Island (FL)  
423 ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial  
424 relationships with ineligible companies. Disclosure: Mandar Jagtap declares no relevant  
425 financial relationships with ineligible companies.: StatPearls Publishing. Copyright ©  
426 2023, StatPearls Publishing LLC., 2023.
- 427 27. Thording L. EP Single-Use Device Reprocessing by the Numbers. Innovate Health.
- 428 28. Chew DS, Li Y, Cowper PA et al. Cost-Effectiveness of Catheter Ablation Versus  
429 Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical  
430 Trial. *Circulation* 2022;146:535-547.
- 431 29. Agarwal MA, Fonarow GC, Ziaecian B. National Trends in Heart Failure Hospitalizations  
432 and Readmissions From 2010 to 2017. *JAMA Cardiol* 2021;6:952-956.
- 433 30. Navar AM, Kolkailah AA, Overton R et al. Trends in Oral Anticoagulant Use Among  
434 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020. *J Am*  
435 *Heart Assoc* 2022;11:e026723.
- 436 31. Markman TM, Geng Z, Epstein AE et al. Trends in Antiarrhythmic Drug Use Among  
437 Patients in the United States Between 2004 and 2016. *Circulation* 2020;141:937-939.

- 438 32. Chew DS, Wilton SB. Clinical Trials for Atrial Fibrillation—What Do We Know? In:  
439 Vasan RS, Sawyer DB, editors. Encyclopedia of Cardiovascular Research and Medicine.  
440 Oxford: Elsevier, 2018:630-642.
- 441 33. Ueberham L, König S, Pellissier V et al. Admission rates and care pathways in patients  
442 with atrial fibrillation during the COVID-19 pandemic—insights from the German-wide  
443 Helios hospital network. *European Heart Journal - Quality of Care and Clinical*  
444 *Outcomes* 2021;7:257-264.
- 445 34. Hernandez I, He M, Guo J et al. COVID-19 pandemic and trends in new diagnosis of  
446 atrial fibrillation: A nationwide analysis of claims data. *PLoS One* 2023;18:e0281068.
- 447 35. Ubaid MF, John K, Daoudi S et al. PO-01-092 NATIONWIDE TRENDS IN  
448 HOSPITALIZATIONS FOR ATRIAL FIBRILLATION IN THE U.S. BEFORE AND  
449 DURING THE OUTBREAK OF THE COVID PANDEMIC. *Heart Rhythm*  
450 2024;21:S210.
- 451 36. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation  
452 and mortality in heart failure: a community study. *Circ Heart Fail* 2011;4:740-6.
- 453 37. MEPS Sample Persons In-Scope for Part of the Year: Identification and Analytic  
454 Considerations. Medical Expenditure Panel Survey, April 2005: Retrieved from:  
455 [https://meps.ahrq.gov/about\\_meps/hc\\_sample.shtml](https://meps.ahrq.gov/about_meps/hc_sample.shtml).
- 456 38. Bernard D, Cowan C, Selden T, Cai L, Catlin A, Heffler S. Reconciling medical  
457 expenditure estimates from the MEPS and NHEA, 2007. *Medicare Medicaid Res Rev*  
458 2012;2.
- 459 39. Aizcorbe A, Liebman E, Pack S, Cutler DM, Chernew ME, Rosen AB. Measuring health  
460 care costs of individuals with employer-sponsored health insurance in the U.S.: A  
461 comparison of survey and claims data. *Stat J IAOS* 2012;28:43-51.  
462  
463  
464  
465

466 **Figure 1: Trends in Healthcare Expenditures over Time for Individuals with AF**

467 This bar graph shows the trends in mean unadjusted annual total healthcare expenditures for  
 468 individuals with AF broken down by medical service category from 2016 to 2021.



469

470


471

472

473

474 **Central Illustration: Incremental Expenditures with AF Overall and Specific to Individuals**  
475 **with Other Chronic Comorbidities**

476 This figure shows the incremental expenditures of AF alone and among individuals with cancer,  
477 ASCVD, COPD, and HF. Made with BioRender.com (see Supplemental File 1 for publication  
478 license). AF = Atrial Fibrillation. ASCVD = Atherosclerotic Cardiovascular Disease. COPD =  
479 Chronic Obstructive Pulmonary Disease. HF = Heart Failure.



480

481

482

483 **Table 1: Demographics, Comorbidities, and Annual Expenditures of Individuals with and**  
 484 **without AF from 2016-2021**

Variable	All	AF	Non-AF	P Value
Average Annual Weighted Population, N	248,067,064	3,564,763	244,502,302	
Average Annual Sample Size, n	22,583	317	22,266	
Age Categories (%)				
18-44 years old	45.8	2.4	46.4	<0.001
45-64 years old	33.1	19.3	33.3	
65-84 years old	18.8	64.0	18.2	
≥85 years old	2.3	14.3	2.2	
Sex (%)				
Female	51.7	45.7	51.8	<0.001
Male	48.3	54.3	48.2	
Race (%)				

<b>Variable</b>	<b>All</b>	<b>AF</b>	<b>Non-AF</b>	<b>P Value</b>
Non-Hispanic White	62.7	89.0	62.3	<0.001
Hispanic	16.4	3.3	16.6	
Non-Hispanic Black	11.9	4.6	12.0	
Non-Hispanic Asian and Other/Mixed Race	9.1	3.2	9.1	
<b>Marital Status (%)</b>				
Married	51.7	59.7	51.6	<0.001
Widowed/Divorced/ Separated	19.4	34.5	19.2	
Never Married	28.9	5.9	29.2	
<b>Education Level (%)</b>				
GED/High School Diploma	45.0	50.7	44.9	<0.001
Bachelor's Degree	20.9	14.6	21.0	
Master/Doctorate	12.3	19.4	12.2	

<b>Variable</b>	<b>All</b>	<b>AF</b>	<b>Non-AF</b>	<b>P Value</b>
Other Degree	10.1	9.3	10.1	
No Degree	11.8	6.1	11.9	
<b>Census Region (%)</b>				
Northeast	17.5	21.4	17.4	<0.001
Midwest	20.8	25.5	20.8	
South	37.9	37.3	38.0	
West	23.7	15.9	23.9	
<b>Household Income Level (%)</b>				
Poor/Negative	10.4	7.5	10.5	<0.001
Near Poor	3.7	3.4	3.7	
Low Income	11.9	13.9	11.9	
Middle Income	28.5	28.0	28.5	
High Income	45.4	47.2	45.4	
<b>Insurance Status (%)</b>				
Private	58.7	16.8	59.3	<0.001



Variable	All	AF	Non-AF	P Value
Medicare	12.5	78.2	12.7	
Other Public	7.6	4.3	7.7	
Uninsured	21.1	0.7	20.2	
CCI (%)				
0	83.4	50.6	83.9	<0.001
1	11.0	26.3	10.8	
≥2	5.6	23.0	5.3	
Comorbidities (%)				
ASCVD	5.6	34.7	5.2	<0.001
HF	0.7	7.0	0.6	<0.001
Cancer	3.5	12.6	3.4	<0.001
COPD	2.3	9.5	2.2	<0.001
Survey Year (%)				
2016	16.4	15.3	16.4	
2017	16.6	14.4	16.6	

Variable	All	AF	Non-AF	P Value
2018	16.7	15.9	16.7	0.014
2019	16.7	18.2	16.7	
2020	16.8	16.4	16.8	
2021	16.8	19.8	16.8	
Annual Unadjusted Expenditures (Mean ± SD)*				
Total	\$7,392 ± \$67	\$25,451 ± \$1,100	\$7,129 ± \$66	<0.001
Inpatient	\$1,598 ± \$33	\$7,975 ± \$733	\$1,506 ± \$32	<0.001
Prescription	\$1,822 ± \$34	\$6,505 ± \$372	\$1,753 ± \$34	<0.001
Office-Based	\$1,918 ± \$24	\$4,716 ± \$247	\$1,877 ± \$24	<0.001
Outpatient	\$801 ± \$19	\$2,867 ± \$314	\$771 ± \$19	<0.001
Home Health <sup>†</sup>	\$372 ± \$15	\$1,345 ± \$138	\$357 ± \$15	<0.001
ED	\$246 ± \$4	\$715 ± \$90	\$239 ± \$4	<0.001
Other <sup>‡</sup>	\$637 ± \$6	\$1,329 ± \$66	\$626 ± \$7	<0.001

485 Values are % or mean ± standard deviation (SD). COPD = Chronic Obstructive Pulmonary

486 Disease. HF = Heart Failure. ASCVD = Atherosclerotic Cardiovascular Disease. GED = General

487 Educational Development. ED = Emergency Department.

488 \*Expenditures are reported in inflation-adjusted 2021 US dollars.

489 †Home health expenditures are summed as home health agency and home health non-agency  
490 expenditure MEPS variables.

491 ‡Other expenditures are summed as dental, vision, and other expenditure MEPS variables.

492

493

494

495 **Table 2: Incremental Expenditures with AF among Individuals with Other Common**  
 496 **Chronic Comorbidities from Gamma Regression**

Sub population	Average Annual Sample Size, n	Average Annual Weighted Population, N	AF Prevalence	Incremental Expenditure with AF (95% CI)
Cancer*	814	8,706,309	5.1%	\$11,967 (\$4,410-\$19,525)
COPD	581	5,705,185	5.9%	\$8,104 (\$2,594 - \$13,613)
ASCVD	1,388	13,846,252	8.9%	\$6,721 (\$3,684 - \$9,758)
HF	176	1,640,324	15.3%	-\$2,756 (-\$10,048 - \$4,535)

497 Values are average marginal effect (95% CI) of having AF from a gamma regression of  
 498 individuals with a given comorbidity. Expenditures are reported in inflation-adjusted 2021 US  
 499 dollars. CI = Confidence Interval. AF = Atrial Fibrillation. COPD = Chronic Obstructive  
 500 Pulmonary Disease. ASCVD = Atherosclerotic Cardiovascular Disease. HF = Heart Failure.

501 \*Due to low sample size in subcategories, the insurance status variable was excluded from the  
 502 gamma regression model for individuals with cancer to enable convergence.

503

504

505 **Table 3: Factors Associated with Increased Total Healthcare Expenditures Among**  
 506 **Individuals with AF from Gamma Regression**

	<b>OR (95% CI)</b>	<b>P Value</b>
Age Categories		
65-84 years old (Ref)		
18-44 years old	1.37 (0.35-5.34)	0.648
45-64 years old	0.85 (0.33-2.16)	0.729
≥85 years old	1.10 (0.89-1.34)	0.381
Sex		
Male (Ref)		
Female	0.92 (0.79-1.07)	0.274
Survey Year	1.07 (1.03-1.12)	0.002
Race/Ethnicity		
Non-Hispanic White (Ref)		
Hispanic	0.98 (0.73-1.32)	0.896

	<b>OR (95% CI)</b>	<b>P Value</b>
Non-Hispanic Black	0.90 (0.63-1.27)	0.545
Non-Hispanic Asian and Other/Mixed	1.15 (0.65-2.04)	0.638
Modified CCI		
0 (Ref)		
1	1.28 (1.07-1.54)	0.009
≥2	1.95 (1.53-2.50)	<0.001
Comorbidities		
Cancer	1.76 (1.35-2.29)	<0.001
ASCVD	1.37 (1.17-1.60)	<0.001
COPD	1.31 (1.01-1.69)	0.039
HF	1.20 (0.95-1.52)	0.124
Education		
GED/HS Grad (Ref)		
No Degree	0.79 (0.59-1.06)	0.110

	<b>OR (95% CI)</b>	<b>P Value</b>
Bachelor's	1.19 (0.93-1.54)	0.168
Master/Doctorate	1.20 (0.95-1.51)	0.124
Other Degree	0.83 (0.66-1.03)	0.096
Marital Status		
Married (Ref)		
Widowed/ Divorced/ Separated	1.12 (0.97-1.29)	0.108
Never Married	1.04 (0.76-1.43)	0.798
Household Income Level		
High Income (Ref)		
Poor	1.39 (1.02-1.88)	0.037
Near Poor	1.11 (0.86-1.45)	0.398
Low Income	1.04 (0.84-1.28)	0.724
Middle Income	1.14 (0.98-1.33)	0.099
Insurance Status		
Medicare (Ref)		

	<b>OR (95% CI)</b>	<b>P Value</b>
Private	1.78 (0.66-4.78)	0.254
Other Public	1.18 (0.42-3.28)	0.749
Uninsured	1.83 (1.13-2.96)	0.014

507 OR = Odds Ratio. CI = Confidence Interval. CCI = Charlson Comorbidity Index. COPD =  
508 Chronic Obstructive Pulmonary Disease. HF = Heart Failure. ASCVD = Atherosclerotic  
509 Cardiovascular Disease. AF = Atrial Fibrillation. GED = General Education Development. Grad  
510 = Graduate. HS = High School. Ref = Reference.

511



512 **Supplemental Table 1: ICD-10 Code Definitions for Other Chronic Comorbidities**

513

<b>Medical Condition</b>	<b>ICD-10 Codes</b>
Heart Failure	I09, I11, I13, I25, I42, I43, I50, P29
Atherosclerotic Cardiovascular Disease	H34, I20-I25, I60-I69, G45, G46, I70, I71, I73, I77, I79, K55, Z95
Cancer	C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C77-C80, C81-C85, C88, C90-C97
Chronic Obstructive Pulmonary Disease	J41-J44


514 ICD = International Classification of Diseases.

515

516

517

### CENTRAL ILLUSTRATION: Incremental Expenditures with Atrial Fibrillation (AF) Overall and Specific to Individuals with Other Chronic Comorbidities



See C, et al.

**Central Illustration:** This figure shows the incremental expenditures of AF alone and among individuals with cancer, ASCVD, COPD, and HF. Made with BioRender.com (see Supplemental File 1 for publication license). AF = Atrial Fibrillation. ASCVD = Atherosclerotic Cardiovascular Disease. COPD = Chronic Obstructive Pulmonary Disease. HF = Heart Failure.